Teva Halts Phase 2 Emrusolmin Trial in Multiple System Atrophy After Futility Analysis

Bitget2026/11/02 13:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Teva will discontinue its Phase 2 TOPAS-MSA trial of emrusolmin in adults with multiple system atrophy.
Interim findings indicated a low probability of meeting the primary efficacy goal; no safety concerns emerged.
The interim assessment was not a final efficacy analysis; comprehensive findings will be shared with the scientific community following further analysis.
A review will include available open-label extension data; the broader emrusolmin program, partnered with MODAG, remains without a final decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800OMX_____CNEWS_EN_GNW1001301263_en) on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Teva Halts Phase 2 Emrusolmin Trial in Multiple System Atrophy After Futility Analysis

You may also like

Crypto prices